Compare Abbott Laboratories (ABT) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Consumer Staples Select Sector SPDR Fund — how do they compare? Abbott Laboratories trades at $110.28 (market cap $187.95B), while Consumer Staples Select Sector SPDR Fund trades at $84.91. The key difference: Abbott Laboratories pays a 2.32% dividend while Consumer Staples Select Sector SPDR Fund pays none, and Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | XLP | |
|---|---|---|
Market Cap | $187.95B | — |
Sector | Health | — |
52-Week High | $136.62 | $90.00 |
52-Week Low | $82.57 | $75.61 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
XLP, the Consumer Staples Select Sector SPDR ETF, trades at $84.585, down 0.43% today. Technical indicators show a neutral overall signal with bullish moving averages, while oscillators remain neutral. The ETF's 2.6% dividend yield provides income appeal, with a dividend scheduled for payment on June 24, 2026. Recent news highlights consumer staples as a defensive play amid market rotation, with Coca-Cola's strong Q2 2026 earnings underscoring sector resilience (ETF Trends, July 29, 2026).
Outlook remains positive given 100% analyst buy ratings and defensive positioning during economic uncertainty. Key risks include sector concentration and sensitivity to consumer spending shifts. The ETF's stability and income generation support a favorable risk-reward profile for conservative investors seeking exposure to essential consumer goods.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
